Practical use of AbobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy
DOI:
https://doi.org/10.5935/0104-7795.20170030Keywords:
Disabled Children, Cerebral Palsy, Muscle Spasticity, Botulinum Toxins, Type AAbstract
AbobotulinumtoxinA (ABO) has been used for the treatment of spasticity in children with cerebral palsy (CP). Its use requires careful administration, regarding dosing, selection of local of application, interval between applications and efficacy and safety monitoring. This was the first panel of experts on the treatment of spasticity, which developed a guide to provide an overview on important issues related to therapeutic strategies adopted by physicians using ABO, including its dosage to be applied per muscle.Treatment should be initiated as soon as possible, ideally between two and six years old. A clinical evaluation should identify muscles presenting spastic activity, and determine desired outcome: improvement of function, esthetics/aspect, pain treatment, easing care and positioning, preventing hips dislocation, improvement of walking and posture, and to provide conditions for education and social participation. Pre-requisites to achieve good results are adequate muscle selection, adequate ABO dosage and exact injection technique. Many common pathological patterns can be adequately treated if several muscles are simultaneously injected in a single treatment session; planning ABO dosage per muscle should take into consideration the maximum dosage in units per muscle and the total maximum ABO dosage per session (30 U/kg patient´s body weight, not exceeding 1000 U).After application children should be submitted to physical therapy and occupational therapy, focused on home therapy, and family involvement, increasing chances of therapeutic gain. Treatment with ABO is multidisciplinary and requires integrated approaches.
Downloads
References
Teles MS, Mello EMCDL. Toxina botulínica e fisioterapia em crianças com paralisia cerebral espástica: revisão bibliográfica. Fisioter Mov. 2001;24(1):181-90.
Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8-14.
Leite JMRS, Prado GF. Paralisia cerebral: aspectos fisioterapêuticos e clínicos: artigo de revisão. Rev Neurocienc. 2004;12(1):41-5.
Friedman BC, Goldman RD. Use of botulinum toxin A in management of children with cerebral palsy. Can Fam Physician. 2011;57(9):1006-73.
Placzek R, Siebold D, Funk JF. Development of treatment concepts for the use of botulinum toxin a in children with cerebral palsy. Toxins (Basel). 2010;2(9):2258-71. DOI: http://dx.doi.org/10.3390/toxins2092258
Molenaers G, Van Campenhout A, Fagard K, De Cat J, Desloovere K. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop. 2010;4(3):183-95. DOI: http://dx.doi.org/10.1007/s11832-010-0246-x
Sheean G. The pathophysiology of spasticity. Eur J Neurol. 2002;9 Suppl 1:3-9. DOI: http://dx.doi.org/10.1046/j.1468-1331.2002.0090s1003.x
Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl. 1997;6:S1-13. DOI: http://dx.doi.org/10.1002/(SICI)1097-4598(1997)6+<1::AID-MUS2>3.0.CO;2-D
Meythaler JM. Concept of spastic hypertonia. Phys Med Rehabil Clin N Am. 2001;12(4):725-32. DOI: http://dx.doi.org/10.1016/S1047-9651(18)30029-9
Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair. 2003;17(1):66-70. DOI: http://dx.doi.org/10.1177/0888439002250449
Candido A. Paralisia cerebral: abordagem para o pediatra geral e manejo multidisciplinar [Monografia]. Brasília: Hospital Regional da Asa Sul; 2004.
Rotta NT. Cerebral palsy, new therapeutic possibilities. J Pediatr (Rio J). 2002;78(suppl 1):S48-S54. DOI: http://dx.doi.org/10.2223/JPED.850
Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691-8. DOI: http://dx.doi.org/10.1212/01.wnl.0000311391.00944.c4
Smania N, Colosimo C, Bentivoglio AR, Sandrini G, Picelli A. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey. Funct Neurol. 2013;28(4):253-8.
Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1-9. DOI: http://dx.doi.org/10.1007/s40268-014-0077-1
Strobl W, Theologis T, Brunner R, Kocer S, Viehweger E, Pascual-Pascual I, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7(5):1629-48. DOI: http://dx.doi.org/10.3390/toxins7051629
Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, Russo RN.Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:38-56. DOI: http://dx.doi.org/10.1111/j.1468-1331.2010.03127.x
Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:9-37. DOI: http://dx.doi.org/10.1111/j.1468-1331.2010.03126.x
Bakheit AM, Severa S, Cosgrove A, Morton R, Roussounis SH, Doderlein L, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol. 2001;43(4):234-8. DOI: http://dx.doi.org/10.1017/S0012162201000445
Blaszczyk I, Foumani NP, Ljungberg C, Wiberg M. Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy. Toxins (Basel). 2015;7(11):4645-54. DOI: http://dx.doi.org/10.3390/toxins7114645
Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214-23. DOI: http://dx.doi.org/10.1111/j.1469-8749.1997.tb07414.x
Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1):45-66. DOI: http://dx.doi.org/10.1016/j.ejpn.2009.09.005
Chung CY, Chen CL, Wong AM. Pharmacotherapy of spasticity in children with cerebral palsy. J Formos Med Assoc. 2011;110(4):215-22. DOI: http://dx.doi.org/10.1016/S0929-6646(11)60033-8
Pascual-Pascual SI, Herrera-Galante A, Póo P, García-Aymerich V, Aguilar-Barberà M, Bori-Fortuny I, et al. Guidelines for the treatment of child spasticity using botulinum toxin. Rev Neurol. 2007;44(5):303-9.
Msall ME, Park JJ. Neurodevelopmental management strategies for children with cerebral palsy: optimizing function, promoting participation, and supporting families. Clin Obstet Gynecol. 2008;51(4):800-15. DOI: http://dx.doi.org/10.1097/GRF.0b013e31818a0431
Baiocato AC, Rozestraten FS, Oliveira TR, Carvalho CMM. O uso da toxina botulínica tipo A como coadjuvante no tratamento da espasticidade: uma revisão da literatura. Fisioter Mov. 2000;12(2):33-46.
Felice TD, Santana LR. Recursos fisioterapêuticos (crioterapia e termoterapia) na espasticidade: revisão de literatura. Rev Neurociências. 2009;17(1):57-62.
Teive HA, Zonta M, Kumagai Y. Treatment of spasticity: an update. Arq Neuropsiquiatr. 1998;56(4):852-8.
Mayo NE, Korner-Bitensky NA, Becker R. Recovery time of independent function post-stroke. Am J Phys Med Rehabil. 1991;70(1):5-12. DOI: http://dx.doi.org/10.1097/00002060-199102000-00003
Pavone V, Testa G, Restivo DA, Cannavò L, Condorelli G, Portinaro NM, et al. Botulinum toxin treatment for limb spasticity in childhood cerebral palsy. Front Pharmacol. 2016;7:29. DOI: http://dx.doi.org/10.3389/fphar.2016.00029
Py AG, Zein Addeen G, Perrier Y, Carlier RY, Picard A. Evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance. Ann Phys Rehabil Med. 2009;52(3):215-23.
Kiresuk TJ, Sherman RE. Goal attainment scaling: A general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968 Dec;4(6):443-53. DOI: http://dx.doi.org/10.1007/BF01530764
Maathuis KG, van der Schans CP, van Iperen A, Rietman HS, Geertzen JH. Gait in children with cerebral palsy: observer reliability of Physician Rating Scale and Edinburgh Visual Gait Analysis Interval Testing scale. J Pediatr Orthop. 2005 May-Jun;25(3):268-72. DOI: http://dx.doi.org/10.1097/01.bpo.0000151061.92850.74
Vivancos-Matellano F, Pascual-Pascual SI, Nardi-Vilardaga J, Miquel-Rodriguez F, de Miguel-Leon I, Martinez-Garre MC, et al. Guide to the comprehensive treatment of spasticity. Rev Neurol. 2007;45(6):365-75.
Arakaki VC, Cardoso MCC, Thinen NC, Imamura M, Battistella LR. Paralisia cerebral - membros superiores: reabilitação. Acta Fisiatr. 2012;19(2):123-9. DOI: http://dx.doi.org/10.5935/0104-7795.20120019
Capucho PY, Carnier SADC, Souza P, Castro DC, Finocchio AP, Oliveira DM, et al. Paralisia cerebral - membros inferiores: reabilitação. Acta Fisiatr. 2012;19(2):114-22. DOI: http://dx.doi.org/10.5935/0104-7795.20120018
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Acta Fisiátrica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
